Karolina Faysman
Adult Health · Los Angeles, CANPI 1336320407
Payments from drug & device makers
Across 1,445 payments — averaging $752.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$303K
- Johnson & Johnson$171K
- Sobi, Inc$133K
- GSK$94K
- CTI Biopharma Corp.$87K
- Pharmacyclics LLC, An Abbvie Company$67K
- plus $231K from 31 others
What the payments were for
- Consulting fees$36,3623%
- Speaking & faculty fees$795,52373%
- Travel & lodging$217,45020%
- Food & beverage$37,1763%
- Education$1320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,086,642 in reported general payments places this provider in the 95th percentile of 785 adult health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RezurockBelumosudil Mesylate | 46 | $1,191,515 |
| JakafiRuxolitinib Phosphate | 39 | $630,804 |
| OjjaaraMomelotinib Dihydrochloride | 13 | $369,037 |
| RevlimidLenalidomide | 16 | $300,100 |
| BrukinsaZanubrutinib | 27 | $264,840 |
| ImbruvicaIbrutinib | 12 | $222,797 |
| PomalystPomalidomide | 11 | $222,010 |
| Lenalidomide | 15 | $163,374 |
| CresembaIsavuconazonium Sulfate | 14 | $81,127 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 36 | $62,385 |
| EliquisApixaban | 27 | $24,431 |
| Anagrelide Hcl | 14 | $1,091 |
| Acyclovir | 57 | $978 |
| ValacyclovirValacyclovir Hcl | 16 | $624 |
| Tacrolimus | 11 | $583 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sanofi-aventis U.S. LLCRezurock | $11,892 | $1,191,51546 claims |
| Incyte CorporationJakafi | $302,699 | $630,80439 claims |
| GSKOjjaara | $93,635 | $369,03713 claims |
| Bristol Myers SquibbRevlimid | $912 | $300,10016 claims |
| Beigene USA, Inc.Brukinsa | $12,521 | $264,84027 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $67,386 | $222,79712 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $20,938 | $222,01011 claims |
| Astellas Pharma US IncCresemba | $1,325 | $81,12714 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $9,514 | $62,38536 claims |
| PfizerEliquis | $25,704 | $24,43127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 785 adult health providers in California.
Other adult health in Los Angeles
- Linda BuckLos Angeles$170K
- Lisa HinemanLos Angeles$29K
- Tammy HarperLos Angeles$11K
- Jennifer LettsomeLos Angeles$6K
- Melissa LeeLos Angeles$5K
- Jamie YoonLos Angeles$5K
- Siok-Hian Tay-KelleyStanford$611K
- Naomi PesynaAnaheim$141K
- Stacy GrissenEncinitas$82K
- Kimberly PodsadaSan Diego$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.